KLRS net incomeQ2 2026-$11.52M
KLRS net income was -$11.52M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$11.35M a year earlier. For the full fiscal 2025 it was -$43.44M, compared with -$69.17M in fiscal 2024.
Kalaris Therapeutics Inc. (KLRS) financials
For the twelve months ended Jun 30, 2026, Kalaris Therapeutics Inc. reported -$44.26M of net income.
- Net income, TTM
- -$44.26M
- Cash
- $43.17M
- Market cap
- $54.8M
FY2019FY2025
FY2019FY2025
KLRS revenue and earnings growth
KLRS EPSQ2 2026-$0.48
KLRS diluted EPS was -$0.48 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.61 a year earlier. For the full fiscal 2025 it was -$2.85.
KLRS free cash flowQ4 2025-$7.07M
KLRS free cash flow was -$7.07M in fiscal Q4 2025 (ended Dec 31, 2025). For the full fiscal 2025 it was -$38.57M.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $165.0K |
| Research and development | $30.75M | $45.04M | $133.07M | $118.87M | $120.73M | $49.66M | $16.25M |
| Selling, general and admin | $15.40M | $6.69M | $48.26M | $52.33M | $49.08M | $21.65M | $10.62M |
| Operating income | -$46.15M | -$51.73M | -$199.90M | -$171.20M | -$169.82M | -$71.31M | -$26.70M |
| Interest expense | $1.44M | $2.70M | - | - | - | - | - |
| Pre-tax income | -$43.44M | -$69.17M | -$190.54M | -$168.97M | -$170.96M | -$69.78M | -$23.84M |
| Income tax | $0 | $0 | -$126.0K | -$265.0K | $1.01M | - | - |
| Net income | -$43.44M | -$69.17M | -$190.42M | -$168.71M | -$171.96M | -$69.78M | -$23.84M |
| EPS, basic | -$2.85 | -$51.77 | -$42.09 | -$50.60 | -$63.02 | -$59.57 | -$426.42 |
| EPS, diluted | -$2.85 | -$51.77 | -$42.09 | -$50.60 | -$63.02 | -$59.57 | -$426.42 |
| Diluted shares | 15.3M | 1.3M | 4.5M | 3.3M | 2.7M | 1.2M | 55,910.13 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $98.05M | $1.64M | $90.12M | $106.09M | $201.66M | $122.66M | $61.08M |
| Short-term investments | $19.93M | $0 | $93.82M | $127.70M | $46.46M | $233.66M | $64.99M |
| Current assets | $118.81M | $2.61M | $187.63M | $243.05M | $253.35M | $361.32M | $127.31M |
| Total assets | $121.74M | $6.16M | $190.80M | $277.08M | $286.59M | $370.82M | $139.42M |
| Current liabilities | $9.71M | $24.70M | $28.37M | $24.34M | $37.85M | $12.29M | $9.11M |
| Total liabilities | $42.92M | $56.78M | $45.02M | $52.56M | $61.33M | $17.76M | $17.80M |
| Shareholders' equity | $78.81M | -$96.62M | -$45.02M | $224.52M | $225.27M | $353.06M | -$51.50M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$38.37M | -$20.67M | -$124.45M | -$142.05M | -$106.32M | -$60.81M | -$20.16M |
| Capital expenditures | $200.0K | - | - | - | $26.0K | $235.0K | $339.0K |
| Free cash flow | -$38.57M | - | - | - | -$106.34M | -$61.05M | -$20.49M |
| Investing cash flow | -$19.72M | $95.00M | $37.98M | -$80.48M | $185.98M | -$169.50M | -$64.64M |
| Financing cash flow | $155.01M | $19.14M | $70.50M | $126.96M | $232.0K | $291.98M | $120.92M |
| Stock-based compensation | $1.94M | $895.0K | $40.78M | $41.31M | $43.98M | $9.43M | $2.89M |
| Depreciation and amortization | - | - | $398.0K | $723.0K | $189.0K | $73.0K | $19.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating margin | - | - | - | - | - | - | -16182.4% |
| Net margin | - | - | - | - | - | - | -14447.9% |
| Free cash flow margin | - | - | - | - | - | - | -12420.6% |
| Return on equity | -55.1% | - | - | -75.1% | -76.3% | -19.8% | - |
| Return on assets | -35.7% | -1122.5% | -99.8% | -60.9% | -60.0% | -18.8% | -17.1% |
| Current ratio | 12.23 | 0.11 | 6.61 | 9.99 | 6.69 | 29.39 | 13.98 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $9.02M | $7.57M | $7.16M | $9.13M | $8.44M | $6.03M | $3.85M | $36.02M | $3.21M | $1.96M | $33.37M | $34.16M |
| Selling, general and admin | $3.37M | $4.26M | $3.64M | $3.62M | $3.82M | $4.32M | $3.28M | $1.83M | $976.0K | $602.0K | $10.46M | $12.80M |
| Operating income | -$12.39M | -$11.83M | -$10.80M | -$12.74M | -$12.26M | -$10.35M | -$7.13M | -$37.85M | -$4.19M | -$2.56M | -$62.41M | -$46.96M |
| Interest expense | $0 | $0 | $0 | $0 | $0 | $1.44M | $1.31M | $815.0K | $499.0K | $78.0K | - | - |
| Pre-tax income | - | - | - | - | - | - | - | - | - | - | -$59.82M | -$44.27M |
| Income tax | - | - | - | - | - | - | $0 | $0 | $0 | $0 | -$126.0K | $0 |
| Net income | -$11.52M | -$10.86M | -$10.00M | -$11.89M | -$11.35M | -$10.20M | -$22.03M | -$38.08M | -$5.65M | -$3.41M | -$59.70M | -$44.27M |
| EPS, basic | -$0.48 | -$0.46 | - | -$0.64 | -$0.61 | -$2.52 | -$16.75 | -$28.16 | -$4.26 | -$2.60 | -$11.96 | -$8.97 |
| EPS, diluted | -$0.48 | -$0.46 | - | -$0.64 | -$0.61 | -$2.52 | -$16.75 | -$28.16 | -$4.26 | -$2.60 | -$11.96 | -$8.97 |
| Diluted shares | 23.8M | 23.7M | - | 18.7M | 18.7M | 4.1M | - | 1.4M | 1.3M | 1.3M | - | 5.0M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $43.17M | $34.43M | $98.05M | $42.39M | $88.43M | $100.97M | $1.64M | $1.91M | $6.24M | $5.23M | $90.12M | $95.63M |
| Short-term investments | $50.37M | $62.79M | $19.93M | $34.61M | - | - | $0 | $5.00M | $24.87M | $54.49M | $93.82M | $117.69M |
| Current assets | $95.92M | $98.47M | $118.81M | $78.18M | $91.65M | $102.18M | $2.61M | $122.53M | $129.94M | $141.48M | $187.63M | $220.02M |
| Total assets | $99.54M | $109.81M | $121.74M | $81.17M | $92.84M | $103.09M | $6.16M | $122.53M | $130.99M | $144.14M | $190.80M | $248.31M |
| Current liabilities | $8.74M | $8.08M | $9.71M | $6.07M | $7.65M | $7.14M | $24.70M | $1.41M | $2.36M | $7.66M | $28.37M | $33.07M |
| Total liabilities | $41.87M | $41.25M | $42.92M | $39.31M | $39.73M | $39.22M | $56.78M | $1.41M | $10.70M | $23.70M | $45.02M | $52.98M |
| Shareholders' equity | $57.67M | $68.56M | $78.81M | $41.87M | $53.12M | $63.87M | -$96.62M | -$89.38M | -$51.53M | -$47.54M | -$45.02M | $195.33M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.05M | -$11.58M | -$7.06M | -$11.33M | -$12.54M | -$7.44M | -$7.85M | -$4.33M | -$3.97M | -$4.52M | -$30.73M | -$34.48M |
| Capital expenditures | - | - | $17.0K | - | - | - | - | - | - | - | - | - |
| Free cash flow | - | - | -$7.07M | - | - | - | - | - | - | - | - | - |
| Investing cash flow | $20.17M | -$50.35M | $14.98M | - | - | - | $5.00M | $20.00M | $30.00M | $40.00M | $25.22M | -$66.85M |
| Financing cash flow | -$377.0K | -$1.70M | $47.74M | $0 | $0 | $107.27M | $7.58M | $1.0K | $4.98M | $6.58M | $11.0K | $0 |
| Stock-based compensation | $644.0K | $580.0K | $333.0K | $638.0K | $591.0K | $374.0K | $280.0K | $262.0K | $322.0K | $31.0K | $9.99M | $10.47M |
| Depreciation and amortization | - | - | - | - | - | - | - | - | - | - | $141.0K | $86.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 10.98 | 12.19 | 12.23 | 12.89 | 11.98 | 14.31 | 0.11 | 86.78 | 55.08 | 18.48 | 6.61 | 6.65 |
Source: XBRL data Kalaris Therapeutics Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-23, first reported Mar 7, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
KLRS peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| KLRS | - | - | -$44.26M | - | $54.8M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
KLRS FAQ
4 questionsIs KLRS profitable?
No. Kalaris Therapeutics Inc. reported a net loss of $44.26M for the twelve months ended Jun 30, 2026.How much cash and debt does KLRS have?
Kalaris Therapeutics Inc. reported $43.17M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did KLRS last report financial results?
The latest statements here come from Kalaris Therapeutics Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.Where does this KLRS financial data come from?
Quantisnow builds these statements from the structured XBRL data Kalaris Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.